Market Segmentation

• Product – CT Devices, MRI Devices, PET Devices, PET-CT Devices and PET-MRI Devices
• Patient Type – Adults and Pediatrics and Infants
• End User – Hospitals and Clinics, Diagnostic Imaging Centers, and Ambulatory Surgical Centers

Regional Segmentation

• North America – U.S. and Canada
• Europe – Germany, U.K., France, Italy, Spain, and Rest-of-Europe
• Asia-Pacific – Japan, China, South Korea, India, Australia and New Zealand, and Rest-of-Asia-Pacific
• Rest-of-the-World – Latin America, and Middle East and Africa

Market Growth Drivers

• Rising Prevalence of Neurological Disorders and Traumatic Brain Injuries (TBI)
• Technological Advancements in the Brain Imaging Modalities and Systems
• Growing Popularity of Molecular Imaging in Brain Imaging

Market Challenges

• Hospital Budget Cuts and High Upfront Cost
• Declining Helium Availability

Market Opportunities

• Integration of Imaging Systems and Software with Novel Biomarkers

Key Companies Profiled

Aspect Imaging, Canon, Inc., Esaote SpA, Fujifilm Holdings Corporation, General Electric Company, Hyperfine Inc., Koninklijke Philips N.V., Mediso Medical Imaging Systems, MinFound Medical Systems Co., Ltd., Samsung Electronics Co., Ltd., Shenzhen Anke High-Tech Co.,Ltd., Shimadzu Corporation, Siemens Healthineers AG, United Imaging Healthcare Co., Ltd., VUNO Co., Ltd.

How This Report Can Add Value

Assuming that the reader is a manufacturer of brain imaging modalities, the report will assist them in the following ways:

• Understand their position compared to other key players in the market
• Stay updated with novel technology integration, features, and the latest developments in the market
• Understand the impact of COVID-19 on brain imaging and the entry barriers for new companies
• Gain insights into end-user perception concerning the brain imaging modalities market
• Identify some key players in the market and understand their valuable contribution

Key Questions Answered in the Report

• How has COVID-19 impacted the growth of the global brain imaging modalities market?
• What are the key regulations governing the brain imaging modalities market in key regions?
• What technological developments are projected to have the maximum influence on the global brain imaging modalities market?
• Who are the leading players holding significant dominance in the global brain imaging modalities market?
• What are some of the growth opportunities which market players can capitalize on?
• What are the drivers and restraints for the global brain imaging modalities market?
• Which region has the highest growth rate in the brain imaging modalities market?
• Which are the fastest growing countries in terms of the global brain imaging modalities market?
• What are the key strategies being adopted by market players in the global brain imaging modalities market?
• Which are the emerging companies in the global brain imaging modalities market?

Global Brain Imaging Modalities Market Industry Overview

The global brain imaging modalities market is projected to witness significant growth during the forecast period 2022-2031. The high prevalence and growing incidences of brain diseases and neurogenerative disorders and the technological advancements in brain imaging modalities and systems are the key propellers for the growth of the market. Five key modalities of brain imaging modalities include computed tomography (CT) devices, magnetic resonance imaging (MRI) devices, positron emission tomography (PET) devices, PET-CT devices, and PET MRI devices. The field of cognitive neuroscience has emerged and developed rapidly over the last 20 years. To address the neural underpinnings of human cognition, this new field combines two traditionally separate disciplines, cognitive psychology and neurology.

The market for brain imaging modalities devices is rapidly growing, with an increasing number of modalities used in the imaging of various brain diseases and neurogenerative disorders (NDs). The high prevalence and growing incidences of neurological disorders (NDs) are one of the major factors augmenting the growth of the global brain imaging modalities market. Neurological diseases and mental disorders have emerged as serious public health concerns and substantial challenges to healthcare systems around the world. Genetic disorders, congenital anomalies or disorders, infections, lifestyle, or environmental health problems such as malnutrition, brain injury, spinal cord injury, or nerve injury are some of the causes of neurological problems.

The global brain imaging modalities market report highlights that the market was valued at $12,334.2 million in 2021 and is expected to reach $20,209.2 million by the end of 2031. The market is expected to grow at a CAGR of 5.06% during the forecast period 2022-2031.

Global Brain Imaging Modalities Market Drivers

Personalized and tailored treatment approaches based on monitoring and imaging findings and respecting pre-injury comorbidities and their therapies are warranted due to traumatic brain injury is a syndrome encompassing a variety of different affections to the brain, and since age-related comorbidities and treatments may also have a significant impact. More importantly, as the prevalence and incidence of neurological illnesses continue to rise, so will technological adoption. As a result, the growth of disease diagnosis and, as a result, the global market for brain imaging modalities will accelerate.

Governments invest a significant amount of money in healthcare insurance so that the overall healthcare costs can be reduced, and the quality of life and affordability of the treatment can be enhanced.

Global Brain Imaging Modalities Market Restraints

The factors restraining the growth of the global brain imaging devices market include the risks associated with radiation exposure and delay in regulatory approvals. Delay in regulatory approval for the products due to the stringent government regulations concerning the use of AI-enabled software in medical imaging hinders the market’s growth. Moreover, another factor restraining the growth of the global brain imaging devices market is the high cost associated with medical imaging.

Global Brain Imaging Modalities Market Opportunities

High growth opportunities in emerging economies and the emergence of local companies in Asia-Pacific and the Middle East and Africa hold immense potential for the global brain imaging modalities market growth. In an era of machine learning and artificial intelligence, extracting quantitative biomarkers from medical images to aid illness detection, characterization, monitoring, and therapy response assessment is becoming increasingly desirable.

Impact of COVID-19 on the Global Brain Imaging Modalities Market

The COVID-19 pandemic had a debilitating impact on the global healthcare ecosystem. Hospitals and clinics faced several challenges such as lack of resources, high patient influx, and risk of infection among care providers. The market is projected to witness considerable growth during the forecast period 2021-2030. The increasing innovations and product designs in the global market and the growing use in emerging economies are the driving factors for the growth of the market.

Market Segmentation

Global Brain Imaging Modalities Market (by Product Type)

The global brain imaging modalities market, based on product type, has been segmented into CT devices, MRI devices, PET devices, PET-CT devices, and PET-MRI devices.

Global Brain Imaging Modalities Market (by Patient Type)

The global brain imaging modalities market, based on patient type, has been segmented into adults, and pediatrics and infants.

Global Brain Imaging Modalities Market (by End User)

The global brain imaging modalities market, based on end user, has been segmented into hospitals and clinics, diagnostic imaging centers, and ambulatory surgery centers surgical centers.

Hospitals and clinics are the major end users for the global brain imaging modalities market. The high volume of the end user makes them the primary diagnosis site for brain diseases and neurodegenerative disorders (NDs) in emerging economies. Furthermore, the adoption of brain imaging modalities in ASCs has been increased due to several factors such as personalized care to the patients and reduced recovery time.

Global Brain Imaging Modalities Market (by Region)

The different regions covered under the global brain imaging modalities market include North America, Europe, Asia-Pacific and Rest-of-the-World.

North America is expected to be the most lucrative region for the global brain imaging modalities market due to advanced healthcare infrastructure and a high focus on research and development activities. The Asia-Pacific brain imaging modalities market is one of the lucrative markets with immense potential for expansion by key players of the global brain imaging modalities market. The Asia-Pacific brain imaging modalities market is expected to grow at the fastest rate during the forecast period. This can be attributed to the massive geriatric population base, which is driving the increase in the volume of brain imaging modalities.

Key Market Players and Competition Synopsis

Some key players operating in the market include Aspect Imaging, Canon, Inc., Esaote SpA, Fujifilm Holdings Corporation, General Electric Company, Hyperfine Inc., Koninklijke Philips N.V., Mediso Medical Imaging Systems, MinFound Medical Systems Co., Ltd., Samsung Electronics Co., Ltd., Shenzhen Anke High-Tech Co.,Ltd., Shimadzu Corporation, Siemens Healthineers AG, United Imaging Healthcare Co., Ltd., and VUNO Co., Ltd.

Some strategies covered in this segment are funding activities, mergers and acquisitions (M&As), partnerships, alliances, business expansion, regulatory and legal activities, and new offerings.

Related report: Brain Disease Modalities and Software Market – A Global and Regional Analysis: Focus on Product, Indication, Patient Type, End User, and Regional Analysis – Analysis and Forecast, 2022-2031

The post Global Brain Imaging Modalities Market – A Global and Regional Analysis: Focus on Product Type, Patient Age, End User, and Regional Analysis – Analysis and Forecast, 2022-2031 first appeared on CRI Report.

Market Segmentation

• Workflow – Discovery, Pre-Clinical Tests, and Clinical Trials
• Products – Software, Software-as-a-Service (SaaS), and Consultancy-as-a-Service
• Technology – Artificial Intelligence, Graphics Processing Unit (GPU), and Other Technologies
• Software – Molecular Modeling and De Novo Drug Design Software, Pharmacophore Modeling Software
• End User – Contract Research Organizations, Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, and Other End Users

Regional Segmentation

• North America: U.S., Canada
• Europe: Germany, France, Italy, U.K., Spain, Russia, and Rest-of- Europe
• Asia-Pacific: Japan, China, India, Australia, South Korea, and Rest-of-Asia-Pacific
• Latin America: Brazil, Mexico, Rest-of-Latin America
• Rest-of-the-World

Market Growth Drivers

• Rising Emphasis on Reduction in Medical Errors
• Technological Advancements in the Field of Computational Biology
• Integration of Blockchain Technology in Interoperability
• Rising Adoption of Cloud-Based Application for Drug Discovery

Market Challenges

• Lack of High Complexity Testing Centers
• Expensive In-Silico Drug Discovery Procedures and Decline in the Number of Approved Drugs
• High Capital Requirement Hampering the Expansion of Global Reach

Market Opportunities

• Massive Scope for Adoption of In-Silico Drug Discovery in Developing Nations
• Adoption of Artificial Intelligence in In-Silico Drug Discovery

Key Companies Profiled

Aragen Life Sciences Pvt. Ltd., Curia Global, Inc., Certara, USA., Charles River, Chemical Computing Group ULC., Collaborative Drug Discovery Inc., Dassault Systemes, e-therapeutics plc., Evotec, Insilico Medicine, Ligand Pharmaceuticals Incorporated, Numerate, Inc., PerkinElmer Inc., Schrödinger, Inc., Selvita, Simulations Plus, Tracxn Technologies, WuXi AppTec

Key Questions Answered in this Report:

• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments:
o Workflow (Discovery, Pre-Clinical Tests, and Clinical Trials)
o Products (Software, Software-as-a-Service (SaaS), and Consultancy-as-a-Service)
o Technology (Artificial Intelligence, Graphics Processing Unit (GPU), and Other Technologies)
o Software (Molecular Modeling and De Novo Drug Design Software, Pharmacophore Modeling Software)
o End User (Contract Research Organizations, Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, and Other End Users)
o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• What are the major market drivers, restraints, and opportunities in the global in-silico drug discovery market?
• What are the underlying structures resulting in the emerging trends within the global in-silico drug discovery market?
• How is each segment of the global in-silico drug discovery market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?
• What are the key developmental strategies implemented by the major players to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions for in-silico drug discovery?
• Who are the leading players with significant offerings to the global in-silico drug discovery market? What is the current market dominance for each of these leading players?
• What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which in-silico drug discovery workflow type has the most promising growth?
• What are the major technologies that are employed in the global in-silico drug discovery market? Which is the dominating technology?
• Who are the primary end users of the global in-silico drug discovery market? Which is the fastest-growing end-user segment in the global in-silico drug discovery market?
• Who are the key manufacturers in the global in-silico drug discovery market, and what are their contributions? Also, what is the growth potential of each major in-silico drug discovery manufacturer?
• What is the scope of the global in-silico drug discovery market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which in-silico drug discovery technology and end user dominate these regions?
• What are the emerging trends in the global in-silico drug discovery market? How are these trends revolutionizing the diagnostic procedure?
• Which technologies are anticipated to break through the in-silico drug discovery regime?
• Which companies are anticipated to be highly disruptive in the future and why?
• Which regulatory procedures are required to unify the approval process for the emerging in-silico drug discovery market? How will these enhance the reimbursement scenario?
• What are the gaps in regularizing in-silico drug discovery adoption in regular healthcare routines? How are these gaps being tackled?

Market Overview

In-silico drug discovery methods can help in identifying drug targets via bioinformatics tools. In addition, the methods can also be used to analyze the target structures for possible binding active sites. The use of computational methods and computers permeates all aspects of drug discovery and drug design. The methods are facilitating the access of massive amounts of data generated and transforming the extensive complex biological data into useful knowledge for the drug discovery process. These computational tools offer the advantage of delivering new drug candidates more quickly and at a lower cost.

Our healthcare experts have found the in-silico drug discovery market to be one of the stable markets, and the global market is predicted to grow from $2,129.8 million in 2020 to $6,515.3 million in 2031 and is expected to grow with a CAGR of 10.52% during the forecast period 2021-2031.

Factors fueling the growth of the market include the rising emphasis on reduction in medical errors, technological advancements in the field of computational biology, and the rising adoption of cloud-based applications in drug discovery procedures. New drug compounds have been developed using computational methods successfully. The developments in computational biology have eased the data analytics and analysis phases of sequencing and have resulted in fewer turnaround times and greater accuracy.

Within the research report, the market has been segmented based on workflow, product, technology, software type, end user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the prevalence of infectious diseases and various types of cancer globally has created a buzz among companies to invest in advanced technologies such as artificial intelligence.

Based on region, North America holds the largest share, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. However, the Asia-Pacific and Europe regions are anticipated to grow at the fastest CAGR during the forecast period.

Related reports: Global E-discovery Market Market Analysis and Forecast Report 2030

The post In-Silico Drug Discovery Market: Focus on Product, Workflow, Technology, and End User – Analysis and Forecast, 2021-2031 first appeared on CRI Report.

Market Segmentation

• Product Type – Personalized and Off-the-Shelf
• Type of Neovaccine – Nucleic Acid Vaccine, Peptide Vaccine, and Dendritic Cell-Based Vaccine
• Therapeutic Specialty – Lung Cancer, Urinary System Cancer, Melanoma, Liver Cancer, Head and Neck Cancer, and Blood and Bone Marrow Cancer
• Line of Therapy – First Line, Second Line, and Later Lines

Regional Segmentation

• North America – U.S. and Canada
• Europe – Germany, U.K., France, Italy, and Spain
• Asia-Pacific and Middle East – China, Australia, Japan, South Korea, and Israel

Market Growth Drivers

• Increasing Global Prevalence of Cancer
• Increase in Adoption of Personalized Medicine to Tailor Patient’s Treatment on an Individual Level
• Significant External Funding for Executing Research and Development Exercise

Market Challenges

• Higher Cost of Personalized Cancer Vaccines
• Hurdles in Clinical Development and Optimization Process
• Uncertain Reimbursement Scenario
• Payer Uncertainty and Outcome-Based Pricing
• High Capital Requirement Hampering the Expansion of Global Reach

Market Opportunities

• Treatment Gaps
• Reduced Turnaround Time and Cost
• Partnerships and Collaboration between Various Healthcare Stakeholders
• Data Analytics

Key Companies Profiled

Moderna Therapeutics, F. Hoffmann-La Roche Ltd, AstraZeneca plc, Agenus, OSE Immunotherapeutics, Advaxis, Medigene, Neon Therapeutics (Acquired by BioNTech SE), Genocea Biosciences, Immunovative Therapies, Gritstone Oncology, Nouscom, NantBioScience, Immunovaccine, BioLineRx, Geneos Therapeutics

Key Questions Answered in this Report:

• What are the major market drivers, challenges, and opportunities in the global neoantigen cancer vaccines market?
• What are the underlying structures resulting in emerging trends within the global neoantigen cancer vaccines market?
• What key development strategies are implemented by the major players in order to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions for neoantigen cancer vaccines?
• How each segment of the market is expected to grow during the forecast period 2024-2031, and what is the estimated revenue to be generated by each of the segments on the basis of:
o Product Type (Personalized and Off-the-Shelf),
o Type of Neovaccine (Nucleic Acid Vaccine, Peptide Vaccine, and Dendritic Cell-Based Vaccine)
o Line of Therapy (First Line, Second Line, and Later Lines)
o Region, including North America, Europe, Asia-Pacific and Middle East
• Who are the leading players with significant offerings to the global neoantigen cancer vaccines market? What is the expected market dominance for each of these leading players?
• Which companies are anticipated to be highly disruptive in the future and why?
• What are the current treatment gaps, and how neovaccines are expected to fill these gaps?
• What are the unmet needs in the global neoantigen cancer vaccine market?

Market Overview

The global neoantigen cancer vaccine industry analysis projects the market to grow at a significant CAGR of 77.73% during the forecast period 2024-2031. The neoantigen cancer vaccine market is expected to generate $35.5 million in revenue in 2024, owing to the expected launch of the first neoantigen vaccine, DC vaccine in the market.

The neoantigen cancer vaccine market growth has been primarily attributed to major drivers in this market, such as rising prevalence of cancers, increasing adoption of personalized medicine to tailor patient’s treatment on an individual level, and significant external funding for executing research and development exercises. However, significant challenges are restraining the market growth. These challenges include the expected higher cost of personalized cancer vaccines, hurdles in clinical development, and payer uncertainty and outcome-based pricing.

Expert Quote on the Neoantigen Cancer Vaccine Market

“The real issues with neovaccines are higher cost, turn-around times, and limited efficacy. The cost and time to manufacture have come down in the last four years, and as technology improves, it will come down more.”

The neoantigen cancer vaccine market report provides a holistic view of the market in terms of various factors influencing it, including reported clinical findings, financing and partnership opportunities, expected market, and current clinical landscape.

The scope of this report is centered upon conducting a detailed study of the products expected to be allied with the oncology market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of key players, growth potential of each underlying sub segment and company, as well as other vital information with respect to the global neoantigen cancer vaccine market.

Pipeline Segmentation

• The emerging neoantigen cancer vaccines are segmented based on product type into personalized and off-the-shelf neovaccines.
• The emerging neoantigen cancer vaccines are segmented based on disease/application into lung cancer, urinary system cancer, melanoma, liver cancer, head and neck cancer, and blood and bone marrow cancer.
• The emerging neoantigen cancer vaccines are segmented based on type of neovaccine into nucleic acid vaccine, peptide vaccine, and dendritic cell vaccine.
• The emerging neoantigen cancer vaccines are segmented based on line of therapy into first, second, and later lines therapy.
• The emerging neoantigen cancer vaccines are segmented based on development phase into Phase I, II, and III.
• The emerging neoantigen cancer vaccines are segmented on the basis of route-of-administration into intradermal, subcutaneous, and intramuscular administrations.

Related report: Global Bladder Cancer Detection Kit Market Analysis and Forecast Report 2030

The post Global Neoantigen Cancer Vaccine Market: Focus on Approach, Line of Therapy, Type, Application, Treatment Strategy, and Country-Wise Analysis – Analysis and Forecast, 2024-2031 first appeared on CRI Report.

Market Segmentation

• Indication – Brain Diseases (Brain and Central Nervous System Cancer, Idiopathic Epilepsy, Ischemic stroke, and Other Brain Diseases) and Neurodegenerative Diseases (Alzheimer’s Disease, Multiple Sclerosis, Parkinson’s Disease, Motor Neuron Disease, and Other Neurodegenerative Diseases)
• Patient Type – Adults and Paediatrics and Infants
• End User – Hospitals and Clinics, Ambulatory Surgery Centers, and Diagnostic Imaging Centers
• Product Type – Brain Imaging Modalities (PET Devices, CT Devices, MRI Devices, PET-CT, and PET-MRI) and Brain Analysis Software

Regional Segmentation

• North America – U.S. and Canada
• Europe – Germany, U.K., Spain, Italy, France, and Rest-of-Europe
• Asia-Pacific – Japan, China, South Korea, India, Australia and New Zealand, and Rest-of-Asia-Pacific
• Rest-of-the-World – Latin America and Middle East and Africa

Market Growth Drivers

• Increasing Prevalence of Neurological Disorders
• Rising AI Integration in the Field of Medical Imaging
• Increasing Demand for Safer and Non-Invasive Devices for Medical Imaging

Market Challenges

• High Upfront Cost of Imaging Devices
• Declining Availability of Helium

Market Opportunities

• Integration of Imaging Solutions with Novel Biomarkers to Enable Diagnosis of a Wider Range of Neurological Disorders
• Integration of 3D Amplified MRI, a New Technological Advancement

Key Companies Profiled

United Imaging Healthcare Co., Ltd., Koninklijke Philips N.V., General Electric Company, Canon, Inc., Siemens Healthineers AG, Vuno Co., Ltd., Fujifilm Holdings Corporation, Aspect Imaging, IXICO, QMENTA, Cortechs.ai, Quantib, Brainomix, Qure.AI, Imaging Biometrics, LLC, A.I. Analysis, Inc.

How This Report Can Add Value

Assuming that the reader is a developer of brain disease modalities and software, they will be able to do the following:

• Understand their position as compared to some of the key players in the market
• Stay updated with novel technology integration, features, and the latest developments in the market
• Understand the impact of COVID-19 on the adoption of brain disease modalities and software and the entry barriers as a result of it
• Gain insights into which regions to target globally based on factors such as the amount of technology integration in medical imaging and the quality of access to affordable medical imaging
• Gain insights into the end user perception with respect to the adoption of imaging modalities and software
• Identify some of the key players in the market and understand their valuable contribution

Key Questions Answered in the Global Brain Disease Modalities and Software Market Report

• How has COVID-19 impacted the adoption of brain imaging modalities and software?
• What are the key regulations governing the brain disease modalities and software market in key regions?
• Which technological developments are projected to have the maximum influence on the global brain disease modalities and software market?
• Who are the leading players holding significant dominance in the global brain disease modalities and software market currently?
• What are the drivers and restraints for the global brain disease modalities and software market?
• Which region has the highest growth rate in the global brain disease modalities and software market?
• Who are the emerging companies in the global brain disease modalities and software market?

Brain Disease Modalities and Software Market Industry Overview

Brain imaging modalities include conventional modalities such as MRI and CT scans and the more emerging imaging technologies such as PET and combined functionalities of PET with MRI or CT. While MRI is a conventional technology due to its age-long usage, various advanced MRI techniques such as diffusion tensor imaging (DTI), diffusion-weighted imaging (DWI), susceptibility-weighted imaging (SWI), and dynamic susceptibility contrast (DSC) imaging are being employed more widely in regions such as North America and Europe.

Brain imaging software offers a valuable addition to the scanned images obtained through these modalities with respect to quantitative analysis. Quantitative insights into the structure, biomarkers, and other subtle abnormalities in the brain are a valuable tool in aiding in a more accurate diagnosis of neurological disorders.

The global brain disease modalities and software market report highlights that the market was valued at $13,055.7 million in 2021 and is expected to reach $21,867.6 million by the end of 2031. The market is expected to grow at a CAGR of 5.31% during the forecast period from 2022 to 2031.

Global Brain Disease Modalities and Software Market Drivers

The market is driven by factors such as the increasing prevalence of neurological disorders, the rising AI integration in the field of medical imaging, and the increasing demand for safer and non-invasive devices for medical imaging.

There has been a paradigm shift in patient preference from invasive to minimally invasive modes of diagnosis as well as treatment. MRI, CT, and PET-CT scans are popular non-invasive methods of medical imaging that produce three-dimensional images of the body to aid in the diagnosis of diseases. Furthermore, there is also a rising preference for safer imaging technologies that employ minimal radiation.

Global Brain Disease Modalities and Software Market Challenges

The factors restraining market growth include the high upfront cost of imaging devices and the declining availability of helium. Hardware devices for medical imaging, such as MRI, CT, and PET-CT scanners, are capital-intensive equipment with a high upfront cost. Lack of affordability is a major factor restraining the growth of the market in emerging economies such as Latin America and Middle East and Africa. Due to the expensive nature of these imaging modalities, there is a considerable lack of accessibility across the population. As a result, the low- and middle-income population usually relies on alternative clinical tests such as blood biomarker tests and cognitive scoring tests as a preliminary method to diagnose neurological disorders.

Furthermore, the shortage of helium globally particularly affects the field of medical imaging in the healthcare sector. MRI scanners require a sufficient quantity of liquid helium, below which the functioning of the scanner is compromised. Therefore, challenges faced by manufacturers of medical imaging modalities associated with the procurement of supercooled liquid helium have a direct effect on the smooth functioning of the machine, thereby hindering the growth of the market.

Global Brain Disease Modalities and Software Market Opportunities

The opportunity for growth of the global brain disease modalities and software market lies in the integration of imaging solutions with novel biomarkers to enable diagnosis of a wider range of neurological disorders and integration of 3D amplified MRI, a new technological advancement in the field of brain imaging.

This new development, i.e., 3D amplified MRI, enables physicians to view pulsations of the brain as opposed to a conventional static MRI image. The real-time visualization of brain movement holds significant potential to detect hard-to-find abnormalities, thereby aiding in the diagnosis process. Companies in the global brain disease modalities and software market can leverage this new technological advancement to gain a competitive edge in the market.

Impact of COVID-19 on the Global Brain Disease Modalities and Software Market

There was a decline in the demand for neuroimaging services as it was offset by the demand for respiratory imaging and tests for COVID-19 treatment. The need to fulfill the demand for critical supplies for COVID-19 management, such as pulse oximeters, ventilators, and oxygen concentrators, overshadowed the demand and supply of the neuroimaging modalities. Although the neuroimaging market is experiencing overall growth, most of the hospitals have reallocated their budget to stock the resources required to fight COVID-19 as they appear to be more crucial.

The COVID-19 pandemic led to government-mandated travel restrictions, especially during the peak phases, leading to a shifting preference among the global population from physical visits to home-based care. This has led to a further push in demand for wearable imaging scanners that can be used at home. They could potentially decrease the demand for hospital-based imaging devices and software due to the ease of providing diagnoses to the patients.

Market Segmentation

Global Brain Disease Modalities and Software Market (by Product)

The global brain disease modalities and software market has been segmented on the basis of product type into brain modalities (PET devices, PET-CT, PET-MRI, CT devices, and MRI devices) and brain analysis software.

Global Brain Disease Modalities and Software Market (by Indication)

The global brain disease modalities and software market has been segmented on the basis of indication into two major segments, namely, brain diseases (brain and central nervous system cancer, idiopathic epilepsy, ischemic stroke, and other brain diseases) and neurodegenerative diseases (Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, motor neuron disease, and other neurodegenerative diseases). Brain diseases could have several underlying causes spanning illness, injury, or genetic manifestations. To diagnose any brain disorder, the initial steps undertaken include preliminary blood tests and understanding the family’s medical background. In addition, an imaging scan is a popular method to detect any abnormalities in brain structure, and tests such as electroencephalogram (EEG) can also be conducted to analyze the underlying electrical activity in the brain.

Global Brain Disease Modalities and Software Market (by Region)

The different regions covered under the global brain disease modalities and software market include North America, Europe, Asia-Pacific, and Rest-of-the-World.

North America and Europe are two of the largest markets for brain disease modalities and software, while developing countries are expected to register strong growth in their adoption in the near future.

Key Market Players and Competition Synopsis

Some of the key players operating in the market include United Imaging Healthcare, Koninklijke Philips N.V., General Electric Company, Canon Inc., Siemens Healthineers AG, Vuno Co., Ltd., Fujifilm Holdings Corporation, Aspect Imaging, IXICO, QMENTA, Cortechs.ai, Quantib, Brainomix, Qure.AI, Imaging Biometrics and A.I., and Analysis, Inc.

In the past few years, the global brain disease modalities and software market has witnessed several strategic and technological developments undertaken by the different market players to attain their respective market shares in this emerging domain. Some of the strategies covered in this segment are funding activities, mergers and acquisitions (M&A), partnerships, alliances, and business expansions, regulatory and legal activities, and new offerings. The preferred strategy for companies has been regulatory and legal activities followed by partnerships and business expansions.

Related: Global Brain Imaging Modalities Market – A Global and Regional Analysis: Focus on Product Type, Patient Age, End User, and Regional Analysis – Analysis and Forecast, 2022-2031

The post Brain Disease Modalities and Software Market – A Global and Regional Analysis: Focus on Product, Indication, Patient Type, End User, and Regional Analysis – Analysis and Forecast, 2022-2031 first appeared on CRI Report.